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Background: Research directed to optimizing maternal nutrition commencing prior to conception remains very
limited, despite suggestive evidence of its importance in addition to ensuring an optimal nutrition environment in
the periconceptional period and throughout the first trimester of pregnancy.
Methods/Study design: This is an individually randomized controlled trial of the impact on birth length (primary
outcome) of the time at which a maternal nutrition intervention is commenced: Arm 1: ≥ 3 mo preconception vs.
Arm 2: 12-14 wk gestation vs. Arm 3: none.
192 (derived from 480) randomized mothers and living offspring in each arm in each of four research sites
(Guatemala, India, Pakistan, Democratic Republic of the Congo). The intervention is a daily 20 g lipid-based (118 kcal)
multi-micronutient (MMN) supplement. Women randomized to receive this intervention with body mass index (BMI)
<20 or whose gestational weight gain is low will receive an additional 300 kcal/d as a balanced energy-protein
supplement. Researchers will visit homes biweekly to deliver intervention and monitor compliance, pregnancy
status and morbidity; ensure prenatal and delivery care; and promote breast feeding. The primary outcome is birth
length. Secondary outcomes include: fetal length at 12 and 34 wk; incidence of low birth weight (LBW); neonatal/
infant anthropometry 0-6 mo of age; infectious disease morbidity; maternal, fetal, newborn, and infant epigenetics;
maternal and infant nutritional status; maternal and infant microbiome; gut inflammatory biomarkers and bioactive
and nutritive compounds in breast milk. The primary analysis will compare birth Length-for-Age Z-score (LAZ)
among trial arms (independently for each site, estimated effect size: 0.35). Additional statistical analyses will examine
the secondary outcomes and a pooled analysis of data from all sites.
Discussion: Positive results of this trial will support a paradigm shift in attention to nutrition of all females of
child-bearing age.
Trial registration: ClinicalTrials.gov NCT01883193.
Keywords: Preconception, Maternal, Nutrition, Birth length, Epigenetics, Microbiome* Correspondence: Michael.Hambidge@ucdenver.edu
1University of Colorado Denver, Aurora, CO, USA
Full list of author information is available at the end of the article
© 2014 Hambidge et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public
Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this
article, unless otherwise stated.
Hambidge et al. BMC Pregnancy and Childbirth 2014, 14:111 Page 2 of 16
http://www.biomedcentral.com/1471-2393/14/111Background
Poor nutrition during pregnancy is a significant con-
tributor to maternal morbidity and a leading cause of
childhood mortality and morbidity worldwide. There is
universal recognition of the importance of the ‘The First
Thousand Days’ for physical growth and, when linear
growth fails during this ‘window of opportunity’, for as-
sociated concurrent and future morbidity and mortality
[1-3]. Sub-optimal nutrition is widely regarded as the
most important etiologic factor contributing to impaired
linear growth in poor communities worldwide. However,
multiple nutrition interventions, whether maternal fol-
lowing identification of pregnancy, or offspring < 2 years
of age have overall met with only partial success [4].
Typically, however, maternal intervention trials have not
begun in the first trimester or/and the periconceptional
period despite observational evidence of a relationship be-
tween poor maternal nutrition at conception and LBW
first reported a quarter of a century ago [5]. A series of
observational and experimental studies suggest that
intra-uterine growth retardation (IUGR), preterm birth
(PTB) and stillbirths have their origins in part in early
pregnancy [6-8]. When the fetus is smaller than expected
in the first trimester, there is increased prevalence of PTB
and IUGR [7,8]. Low maternal weight gain in early preg-
nancy, indicative of sub-optimal maternal nutrition, has
been reported to be a specific cause of LBW attributable
to effects on both length of gestation and on fetal growth
velocity [9]. An intervention improving maternal nutri-
tional status and maternal weight in early pregnancy was
associated with a positive effect on birth length which was
not observed with nutrition interventions starting later in
pregnancy [9]. The results of a recent intervention study
in Bangladesh [10] have demonstrated the importance of
the time of gestation at which a nutrition intervention is
commenced. When the intervention was started in the
first trimester (average of 9 wk gestational age), the benefi-
cial effects on birth weight and even on offspring mortality
were significantly greater than when the same intervention
was commenced at 20 wk. Maternal-infant bonding and
perception of food insecurity also benefited from the first
trimester start [11].
Studies with animal models have demonstrated that
fetal growth and development are most vulnerable to
maternal nutrition deficiencies in early gestation, specif-
ically during the implantation period and that of rapid
fetal development [12]. A similar conclusion has been
based on analyses of observational studies in the human
with the emphasis on the need for well-designed peri-
conceptional intervention trials in developing country set-
tings [13]. Concerns that maternal short stature resulting
from intergenerational effects and the maternal envir-
onment during her own ‘window of opportunity’ may se-
verely limit the benefits of maternal nutrition interventionhave recently been modified [14], in part on the basis of
rapid enhancement in linear growth over one generation
or less when there are major environmental improvements
[15]. To be certain that the effects of any preconception
intervention will be achieved by the time the ovum is
fertilized, the interval between starting the intervention
and conception must be adequate. Extrapolation from ex-
perimental data from dietary-restricted sheep [16] suggests
that such interventions should start ≥ 3 mo prior to con-
ception. Limited human data indicate that the greatest
effects of maternal nutrition supplements on birth weight
have occurred when maternal nutritional status is poor
and when supplements were continued from the previous
pregnancy until the next [17].
Selection of the correct primary outcome for a precon-
ception maternal nutrition trial is critical. A special feature
of this project is the selection of birth length (length-for-
age Z-score, LAZ) as the primary outcome. There are two
reasons for this choice. First is the evidence that birth
length, in contrast to birth weight, is determined primarily
by development early in fetal life [8]. A nutrition interven-
tion for underweight women was associated with a posi-
tive effect on birth length which was not observed when
the intervention was started later in pregnancy [9]. These
results have similarities to the results of the study in
Burkina Faso in which supplements had an effect on
birth weight but not on birth length except on under-
weight women [18]. Birth LAZ is the strongest predictor
of LAZ at least until mid-infancy [19], while weight for
age z-scores (WAZ) at birth have no predictive value of
length in mid-infancy. This is important because it is
retarded linear growth rather than wasting in the first two
years that has the strongest association with infant/young
child morbidity/mortality and with non-communicable
disease later in life.
Increasingly, the argument for commencing maternal
nutrition trials prior to conception is being strengthened
by epigenetic studies. For example, in non-human pri-
mates, manipulation of the diet for relatively short periods
prior to conception can alter the maternal and fetal epige-
nome with corresponding fetal changes in the metabolic
phenotype [20-23]. In the human, periconceptional micro-
nutrient supplementation favorably impacts methylation
patterns in cord blood and in the young infant [24]. The
closer to fertilization, the greater the potential for epigen-
etic changes and corresponding plasticity of the offspring
in response to environmental change. These changes in
the placenta and embryo/fetus provide a very plausible
explanation for the concept of the fetal origins of adult
disease [16]. Though these epigenetic changes are poten-
tially reversible, little is yet known about the speed and
extent of these improvements in response to improvements
in the environment, including the nutrition environment,
nor is it yet known how dependent these are on the prior
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Epigenetic studies are sorely needed in this area.
Maternal nutrition has received relatively little atten-
tion in the context of implementing the United Nations’
Millennium Development Goals (MDG) [25]. This can be
attributed to the lack of a strong evidence base to justify the
huge effort necessary to optimize the nutrition status of vir-
tually all females of reproductive age. Rigorous multinational
trials demonstrating the efficacy of preconception nutrition
in improving offspring outcomes are a critical need.
Objectives and hypotheses
Goal
The goal of this trial is to ascertain the benefits to the
offspring of ensuring optimal human maternal nutrition
before conception, during the peri-conceptional period
and during the entire first trimester.
Objective
The objective is to determine the benefits to the off-
spring of women in poor, food-insecure environments of
commencing a daily comprehensive maternal nutrition
supplement (with additional balanced calorie/protein
supplement for underweight participants) ≥ 3 mo prior
to conception versus the benefits of commencing the
same supplement at 12-14 wk gestation and also to
compare offspring outcomes with those of a third trial
arm who receive no supplement.
Primary hypothesis
In women living in poor, food insecure populations, com-
mencing a maternal nutrition supplement at least 3 mo
prior to pregnancy (Arm 1) will result in significantly
greater fetal linear growth as determined by newborn LAZ
than starting the same nutrition supplement at 12-14 wk
gestation (Arm 2) or than not providing this supplement
(Arm 3).
Secondary hypotheses
Commencing the nutrition intervention prior to concep-
tion will also be associated with:
a. Greater fetal linear growth rate which will be
maintained at least until mid-infancy (6 mo
postpartum);
b. Higher mean birth weight than if the same
supplement is delayed until 12 wk gestation (Arm 2)
or not provided (Arm 3);
c. Decrease in hospital/health center visits/admissions
for sepsis/respiratory disease and diarrhea (and of
calendar recorded morbidity at home);
d. Positive changes in the maternal, placental and
offspring epigenome which may be related to growth
and development of the offspring;e. Distinct differences in the gut and vaginal
microbiota of the mother and gut of the infant;
f. Improvement of maternal and offspring
inflammation and favorable changes in the
nutritional and bioactive components of breast milk
at 2 wk and 3 mo postpartum.
Site description
Rural sites in four countries will participate in a common
trial format, with each site powered independently for
the primary outcome, birth length. The sites are in India
(Belgaum, Karnataka), Pakistan (Thatta, Sind Province),
Democratic Republic of Congo (DRC, Equateur Province),
and Guatemala (Chimaltenango Department), all of which
have a 10-year history of working together primarily on
shared common trials through the Eunice Kennedy Shriver
National Institute for Child Health and Human Develop-
ment (NICHD) Global Network (GN) for Women’s and
Children’s Health Research (http://gn.rti.org).
Trial preparation
Preparatory measures have included the formation of a
Scientific Advisory Committee (membership details pro-
vided in Additional file 1) which has been active in pro-
viding key advice reflected in the final trial protocol,
including the composition of the nutrition interventions.
Another special measure has been to establish the use
of data from the GN Maternal Newborn Health (MNH)
Registry [26] or/and other strategies including home sur-
veys to assess site specific inter-pregnancy intervals and
optimal parity to achieve 50% conception within the
timeline of the trial.
Training is being undertaken by the University of Color-
ado (UCD) team and RTI, the Data Coordinating Center
for the GN and this trial, in both train-the-trainer meet-
ings of all site leaders and by on-site training at each of
the four sites.
A common manual of operations and data collection
tools have been developed by UCD and RTI and trans-
lated by all four sites.
Relevant pilot infant linear growth data have been pro-
vided by two very recent studies [27,28]. Newborn length
data are available only for Guatemala where the mean
Z-score in Chimaltenango Department for a recent cohort
of 148 subjects was −1.0 [19]. Mean (SD) birth weights
derived from recent GN MNH Registry data are: India
2759 (435) g; Pakistan 2974 (522) g; DRC 3134 (478) g;
Guatemala 3018 (478) g.
Other preparatory measures include:
 Ethics committee and local Ministries of Health
approval at each research site and IRB approval at
University of Colorado;
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health services and regional hospitals;
 Contractual arrangements for awards and
subcontracts;
 Community, including civil and local health facility,
approval;
 Development of data collection forms and
preparation of manual of operations;
 Preparation, procurement, analyses, shipment and
import of supplements.
Methods
Study design
This is a 3-armed trial of a comprehensive nutrition sup-
plement commencing at least 3 mo prior to pregnancy
(Arm 1), at 12-14 wk gestation (Arm 2), or not at all
(Arm 3). The trial is an individually randomized, longitu-
dinal, non-masked, controlled trial. It will utilize the GN
MNH Registry to facilitate identification of eligible sub-
jects and will involve four sites in four different countries.
A consort diagram for individual sites is given in Figure 1.
A key feature of this trial is the difference in timing of
starting the intervention, specifically at least 3 mo precon-
ception (Arm 1) vs early 2nd trimester (Arm 2).Figure 1 Consort diagram (subject numbers are for each independenTimeline (in months, commencing December 1, 2012)
0-12 Study preparations
13-18 Enrollment of 1440 eligible participants and base-
line studies
38 Conception of 50% participants in each arm complete
47 All pregnancies completed
53 Maternal/infant follow-up completed (May 30, 2017)
60 Laboratory analyses, data analyses, reporting complete
(Nov 30, 2017)Participants
Eligible participants will be identified primarily through
the GN MNH Registry at each of the four sites.
Nulliparous women will be identified by site-specific
strategies, including home surveys and marriage records.
They will be randomized together with parous women,
identified through the GN MNR, to one of the three
arms.Inclusion criteria
16-35 y of age; parity 0-5; expectation to have first or
additional pregnancy within next 2 y and without intent
to utilize contraception.t site).
Hambidge et al. BMC Pregnancy and Childbirth 2014, 14:111 Page 5 of 16
http://www.biomedcentral.com/1471-2393/14/111Exclusion criteria
Women with hemoglobin (Hb) ≤ 8 g/dL and nulliparous
women who do not agree to hospital delivery (equipped
for caesarian section) or/and do not have ready access to
such a facility. Parous women who have had a previous
history of pre-eclampsia or a history of prolonged labor
associated with cephalopelvic disproportion will be ex-
cluded. Previous caesarian section will not necessarily
exclude participation, a decision which will depend on rea-
son for caesarian and intent to deliver where C-Section
facilities are readily available.
Ethical approval
Each participating research site has received ethical ap-
proval for the conduct of this trial through their local
institutional review board (registered with US Office of
Human Research Protection and with Federal Wide
Assurances in place). The review boards provide initial
review (with enhanced focus on local cultural practices
and laws) and approve and conduct annual reviews of
the trial to monitor enrollment, retention, and adverse
events among other important issues. Importantly, each
site has cultivated relationships with its Ministry of
Health and community leaders in order to obtain input
from communities and help ensure acceptance and
effective implementation of community-based trials.
All participants will provide written informed consent
prior to participation.
Study procedures
Enrollment
The optimal time post-partum for enrollment will vary
by site; enrollment may start as early as 4 mo postpartum,
but may be delayed until 8 mo depending on site-specific
inter-pregnancy intervals. For nulliparous women, timing
should be at least 4 mo before the estimated conception.
Enrollment will occur after screening and informed con-
sent in the home by the Home Visitor Research Assistant
(HVRA) if inclusion criteria are met and there are no
exclusionary criteria. Hb will be measured using blood
from a finger stick and Hemocue™ instrumentation in all
women. Enrollment of eligible women at each of the four
participating sites will be undertaken over a 6 mo period.
Prior to enrollment, potential participants will be advised
that they will exit the trial if conception occurs before 3
mo of the biweekly home visits or if they are not among
the first half of Stage 1 participants whose conception is
confirmed after this first 3 mo period.
Randomization
Generation of the allocation sequence separately for each
site has been undertaken by RTI International. A per-
muted block design with stratification by geographic clus-
ter was used to generate the randomization sequence forassigning individual participants to a trial arm. The num-
ber of assignments to Arms 1, 2, and 3 were allocated with
a ratio of 1:1:1 within blocks randomly varied in size
between 3, 6, and 9. Stratification by cluster was used to
ensure a similar number of participants randomized to
each arm within cluster in order to provide geographic di-
versity across arms and for operational convenience given
that the trial infrastructure in each country is organized
around these clusters.
As each subject is enrolled, the responsible HVRA will
contact the site data manager who will key the screening
identification number into a computerized data man-
agement system (DMS) dedicated to the randomization
process of enrollment.
Baseline data includes:
Questionnaires Demographic information (including
SES, water supply, sanitation, parental education and
occupation); site-specific household food insecurity ques-
tionnaire [29] and indoor air pollution assessment. Ques-
tionnaires will be administered in the home by the local
HVRA and will be completed within 1 wk of enrollment.
Medical history and anthropometry A mobile assess-
ment team will obtain past medical and obstetric history;
anthropometric data from the mother including height
and weight with calculation of body mass index (BMI);
mid-upper arm circumference (MUAC); waist and hip
circumference; and head circumference. A pregnancy test
will be conducted to ensure that the participant is not
pregnant. Paternal anthropometric measurements includ-
ing height and weight will also be obtained at baseline
whenever possible.
Biological sample collection A phlebotomist will ac-
company the assessment team and collect a 0.5 mL venous
or fingerstick blood sample from all willing participants in
all three trial arms for Hb and dried blood spot collections.
Intervention The nutrition intervention will be a multi-
micronutrient (MMN) fortified lipid-based supplement
(Nutriset, Malauney, France). In addition to the MMN
and polyunsaturated lipids (linoleic 4.9 g and α-linolenic
0.59 g), the composition includes dried skimmed milk,
soybean and peanut extract, sugar, maltodextrin stabi-
lizers, and emulsifiers. The specific preparation is a modi-
fication of Nutributter by iLiNS based at UC Davis for
research use with pregnant and lactating women (LNS
P&L). This preparation is currently in use in studies in
Ghana and Malawi where it has had formal acceptability
testing. The micronutrient content of the daily 20 g
supplement to be administered in this trial (Table 1) is
unchanged from the LNS P&L except for an increase
in the Vitamin D to conform to a recent update in the
Table 1 Nutrient content of lipid-based nutrition supplementation preparation (20 g daily portion)
Nutrient Amt Nutrient Amt Nutrient Amt
Energy, kcal 118 Iron, mg 20 Thiamine (B1), mg 2.8
Protein, g 2.6 Magnesium, mg 65 Vitamin A, μg 800
Fat, g 10 Manganese, mg 2.6 Vitamin B12, μg 5.2
Linoleic acid, g 4.59 Niacin, mg 36 Vitamin B6, mg 3.8
α-Linolenic acid, g 0.59 Pantothenic acid (B5), mg 7 Vitamin C, mg 100
Calcium, mg 280 Phosphorous, mg 190 Vitamin D2, IU 1000
Copper, mg 4 Potassium, mg 200 Vitamin E, mg 20
Folate, μg 400 Riboflavin (B2), mg 2.8 Vitamin K, μg 45
Iodine, μg 250 Selenium μg 130 Zinc, mg 15
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to allow for potentially lower bioactivity of the ergo-
calciferol form chosen for acceptability to vegetarian
populations. The zinc content was reduced to a level
close to the recommendation of the Institute of Medicine
for pregnant women [31]. The LNS P&L is water-free and
has a long shelf life of 18 mo at room temperature in hot,
humid environments.
The intervention will be initiated in Arm 1 within 2 wk
of enrollment to give time for baseline studies and in Arm
2 once participants in Stage 2 reach 12 wk gestation and
have completed dietary assessments (if applicable), anthro-
pometry measurements and biospecimen collection, and
ultrasound exams. For each of these two arms, the inter-
vention will be terminated at delivery.
Fourteen daily supplements will be provided biweekly
in 20 g sachets with instructions to take one sachet per
day. A rodent and water resistant plastic container will be
provided to each participant for storage of the sachets.
The supplement can be eaten as is or mixed in with other
foods depending on the preference of the participant. A
record will be maintained indicating if sachet is taken
alone or with meals. Instructions will be given to the par-
ticipant that although the supplement can be added to
other foods before eating, it should not be added to foods
while cooking.
Follow-up procedures: stage 1 (Preconception)
Biweekly home visits and assessment for all three arms
(more frequently for first 2 wk or for longer period if
issues with compliance) will commence within 2 wk of
enrollment. Menstrual history will be obtained at each
visit and a urine pregnancy test will be performed if last
menstrual period (LMP) was > 4 wk prior or mother
thinks she might be pregnant. Pregnancy testing will also
be undertaken at every visit after the first 3 mo postpar-
tum if menses have not yet resumed or are irregular.
Maternal morbidity will be monitored at each visit for all
participants. A calendar will be provided to the women
and they will be trained to record history of morbidity andmenses on a daily basis. Discussion will include plans for
prenatal care, location of delivery, and exclusive breast-
feeding support (late 3rd trimester onwards). Women in
Arm 1 will be weighed monthly and BMI calculated by the
Field Supervisor. The HVRAs will be supported wherever
possible by local community volunteers or/and health
workers (especially in India and by nurses in the wide-
spread DRC communities).
Compliance of supplement use will be monitored by
self-reported history and sachet collection during biweekly
visits. Women will also mark off daily supplement compli-
ance on the calendar noted above. Compliance will also
include random independent audits by other research
personnel.
Results of monthly weight checks for Arm 1 partici-
pants will identify those with BMI ≤ 20 initially or at any
subsequent stage and those participants will receive
an additional balanced protein/energy (300 kcal/d; 12%
calories from protein and no added micronutrients;
Nutriset, Maluaney, France) supplement, and weight
will be monitored monthly. Once initiated, the second
supplement will be continued until the end of the trial or
the completion of pregnancy, whichever is the soonest.
Participants on the intervention will be cautioned not
to take other micronutrient supplements or fortified
supplemental foods while on the trial intervention. Use
of additional supplements will be monitored and re-
corded at the monthly assessment visits conducted by
the assessment team.
Follow up procedures: stage 2 (Pregnancy)
The first 240 participants in each arm at each site to
conceive after 3 mo will enter Stage 2 (participants must
have received at least 3 mo nutrition intervention/home
visits). The remaining participants in Stage 1 will discon-
tinue the trial. An exit visit will include Hb measure-
ment (Hemocue™) and appropriate referral as necessary
for follow-up care.
Biweekly visits by the HVRA will continue as before
for pregnant participants retained in the trial. The HVRA
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pital delivery. The HVRA or supervisor will also be in con-
tact with the individual/facility responsible for delivery
and this will be on a longitudinal basis in the case of com-
munity birth attendants and home deliveries. Participants
in Arm 2 will be advised to stop taking iron and folate
supplements once they start the nutrition intervention at
12 wk gestation. Participants in all arms will be advised at
12-14 wk gestation to commence prenatal care, which, in
the case of Arm 3, may include supplements provided by
caregiver.
During pregnancy, monthly weight checks will con-
tinue for Arm 1 and be initiated for Arm 2 at the time
the nutrition supplement is started. Extra energy/protein
supplement (see above) will be provided for women in
Arms 1 and 2 if 2nd and 3rd trimester pregnancy weight
gain fails to reach recommended guidelines (approximately
2 kg/mo for underweight and normal weight women and
1 kg/mo for overweight and obese women).
Dietary assessment Half of the trial women in both
Arm 1 and Arm 2 will be selected for a dietary assess-
ment at the biweekly visit when pregnancy is confirmed.
A research nutritionist will obtain two multiple-pass 24-h
dietary recalls (2-4 wk apart) from every other participant
in Arms 1 and 2 prior to 12 wk gestation (i.e. 120/arm,
240/site). Both 24-h dietary recalls will be conducted in
the participant’s home.
Assessment visits At 12 and 34-36 wk gestation, mater-
nal anthropometry will be conducted for women in all
arms and Hb will be repeated (with referral for care if
Hb <8 g/dL). Biological samples, including maternal
blood (30 mL), spot urine, and stool will be conducted
for women in Arms 1 and 2. If the participant declines
to provide a venous blood sample, research personnel
will request an optional simple finger stick for blood
spot collections. Methods for processing and storage
while maintaining cold chain will be carefully adhered
to. HVRA will also accompany participants in all arms
to the health center or district hospital for fetal ultra-
sounds at 12 and 34-36 wk gestation, organizing trans-
port as necessary. Only after completion of the 12 wk
gestation assessment visit will Arm 2 commence the
same nutrition supplement as Arm 1. Arm 3 will continue
to receive biweekly visits monitoring maternal infectious
disease morbidity and MUAC.
Monthly weight checks will continue and extra energy/
protein will be provided to women in Arms 1 and 2
who do not maintain recommended weight gain during
pregnancy (see above). Pregnancy complications will be
recorded as adverse events. These include miscarriages
and still births, with estimation of gestational age of
latter and weight when feasible.Follow up procedures: stage 2 (Delivery)
For women in all arms, deliveries will whenever possible
be in local birth facilities/regional hospitals. Whenever
trained hospital personnel are at the delivery and mother
provides consent, they will collect amnion and, after de-
layed cord clamping, cord blood. Maternal blood, stool
sample and vaginal swab will also be collected. Infant
birth length [32] and weight will also be obtained from
all participants within 12 h of delivery. This applies to
home as well as hospital deliveries and a team will be on
call at weekends for the 12 h measurements.
Nutrition supplements will be discontinued at time of
delivery for Arms 1 and 2.
Follow up procedures: stage 2 (Postpartum)
Biweekly visits by the HVRA will continue as before.
HVRA will record all severe maternal morbidity and infant
morbidity requiring health center/hospital visits admission
for malaria, unspecified fever, respiratory disease, or diar-
rhea. Morbidity cared for at home will also be recorded
with assistance of initial participant education and calen-
dar. The project coordinator will be alerted in case of neo-
natal/infant mortality and need for verbal autopsy. For all
of these duties, HVRAs will be supported and monitored
by field supervisors. The HVRAs will also check on details
of infant feeding at each visit, supporting exclusive breast
feeding; noting any other fluids given with details and also
when first weaning foods are offered if before 6 mo.
Assessment visits will be conducted at 14-d, 1, 3, and 6
mo of age to collect neonatal and infant anthropometry
for offspring of women in all arms by members of the
Assessment Team. Maternal weight will also be mea-
sured at 6 mo visit. An optional blood sample will be
collected at 14 d and at 3 mo postpartum for women in
Arms 1 and 2 and at 3 mo postpartum in Arm 3. For in-
fants in all trial arms, optional blood collection will be
limited to a fingerstick at 2 wk and at 3 mo of age, with
parental consent. From previous experience it is esti-
mated that 50% of subjects will consent to blood collec-
tions. The HVRA will assist the participant in collecting
20 mL hand expressed breast milk at 14 d and 3 mo
postpartum. All samples will be collected, stored, proc-
essed, and transported maintaining cold chain.
A summary of study procedures for each participant is
shown in Tables 2, 3 and 4.
Outcome measures
Primary outcome: birth length-for-age Z-score
Highly trained Research Assistants (Assessment Team)
will obtain these early neonatal length measurements at
12 h of age (neonatal stadiometer, Ellard Instrumenta-
tion, Ltd, Monroe, WA), with skills that include gentle
solicitation of a Babinski response to achieve feet at right
angles to the lower limbs [32].
Table 2 Summary of study procedures for Stage 1 of participation
Stage 1: Preconception Week of participation
0 1 2 until conception
Screening/Consent X
Enrollment/Randomization* X
Baseline data collection X
(SES, environmental, maternal and paternal anthropometry, health hx)
Biweekly home visits (begin within 2 wk of enrollment)
Monitor menses/confirm pregnancy →→→
Primary nutrition intervention (Arm 1) →→→
Energy/Protein supplement (prn, Arm 1) →→→
Maternal Morbidity →→→
MUAC →→→
Maternal monthly weight (Arm 1 only) →→→
Maternal blood sample collection (all arms) X
*Nulliparous women will be enrolled at a point in time estimated to be at least 4 mo before first pregnancy occurs.
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time include infant weight (electronic scales sensitive
to 10 g), head circumference (plasticized measuring tape
accurate to 1 mm), and MUAC with data being converted
to Z-scores automatically by the computer on data entry.
Secondary outcomes
1) Infant LAZ at age 0.5, 1, 3 and 6 mo postnatalTabl
Stage
Biwe
Nutrit
Arm
Arm
Kc
Ma
MU
Dieta
Mate
Fetal
Mate
Mate
Infan
ProceResearch assistants (Assessment Teams) will obtain
infant anthropometry at age 0.5, 1, 3, and 6 mo ofe 3 Summary of study procedures for Stage 2 (pregnancy)
2: Pregnancy & Delivery
ekly home visits
ion intervention
1
2
al/Pro supplement (prn, Arms 1 & 2) prn
ternal morbidity
AC
ry assessment (two, 24-hr recalls in every other participant in Arms 1 & 2
rnal monthly weight
ultrasound
rnal biologic sample collection
rnal anthropometry and vitamin/mineral use
t birth length & weight
dures are for all women in all arms unless otherwise noted.age. Measurements will be converted to Z-scores
using the current WHO growth standards.
2) Estimate longitudinal fetal growth
Ultrasound measurements will be undertaken at 12
and 34-36 wk gestation with the goals of confirming
gestational age (use ultrasound estimate if >7 d different
from LMP estimate) and estimating longitudinal fetal
growth, the latter from repeated measurements of
crown-rump, femur and humeral length. Biparietal
diameter and abdominal circumference will also be
measured. Measurements will be conducted byof participation (timeline begins with conception)
Stage of pregnancy (wk) Delivery
0-12 13-24 25-birth
→ → → → →
→ → →
→ → → → →
→ → → → → X
→ → → → →
) XX
XXX XXX XXX
(Arm 1) (Arms 1 & 2) (Arms 1 & 2)
X (12 wk) X (34-36wk)
X (12 wk) X (34-36 wk) X
(Arms 1 & 2) (Arms 1 & 2)
X (12 wk) X (34-36 wk)
X
Table 4 Summary of study procedures for Stage 2 (postpartum) of participation (timeline begins at delivery)
Stage 2: Postpartum/infant Time postpartum
12 hr 14 d 1 mo 3 mo 6 mo
Neonatal/Infant anthropometry X X X X X
Maternal anthropometry X
Maternal morbidity (biweekly) → → → → → →
Infant morbidity (biweekly) → → → → → →
Breast milk collection X X
Maternal biological sample collection X X
(Arms 1&2)
Infant biological sample collection X X
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Ultrasound reading will be reviewed by local site
expert(s) and a random sample will be reviewed by
a single expert to assure quality control.
3) Mean birth weight and incidence of LBW infants
Incidence of LBW is a recognized risk factor
for mortality and the other peri- and neonatal
outcomes targeted in this proposal, as well as for
later non-communicable disease. Birth weight will
be recorded at delivery.
4) Perinatal mortality
Pregnancy losses >20 wk gestation will be recorded
as stillbirths, together with intrapartum losses,
maternal ‘near deaths’ and neonatal deaths up to 1
mo of age as well as early infancy deaths from 1-6
mo of age. Verbal autopsy results for all neonatal
and early infant deaths will be obtained from the
GN MNH Registry [26].
5) Incidence of severe neonatal and infant infectious
disease
Outcome measure is number of acute visits/
admissions to health center/hospital for severe
infectious disease. Diagnosis and treatment will also
be recorded. It is further intended to collect minor
morbidity data. These data will be obtained with use
of a trial calendar with appropriate training on use
and collected at biweekly home visits. Infant
vaccination history will be recorded at the
assessment visit occurring at 6 mo of age.
Laboratory outcome measures
Activities Common to Secondary Outcomes 6-9.
 Cold chain and cold sample storage facilities will be
obtained/upgraded as necessary at all community
hospital sites (except DRC);
 Specialized training of research personnel to ensure
proper sample collection, transportation and storage.
Vigorous training of birth attendants and otherhospital personnel will be undertaken for collection/
freezing of cord blood and amnion samples;
 Site-specific arrangements will be made for optimal
transport of frozen samples while maintaining cold
chain to UCD for laboratory analyses. Jawaharlal
Nehru Medical College (JNMC) will undertake
laboratory analyses on site to the greatest extent
possible.6) Epigenome of mother, fetus and offspring
Maternal environmentally-induced improvement in
her epigenome provide an appealing hypothesized
mechanism by which this preconception nutrition
intervention is responsible, at least in part, for the
hypothesized resulting phenotypic improvements in
her offspring including pre- and post-natal growth.
In particular it is hypothesized that DNA methyla-
tion patterns in global and gene specific studies will
vary with a maternal nutrition intervention com-
mencing pre-conception vs. 12-14 wk gestation vs.
no maternal nutrition supplement. Patterns will be
compared in DNA from maternal blood (longitudinal);
fetal tissue (amnion); cord blood and infant blood at 3
mo post-partum. Maternal samples will be collected at
baseline (preconception), 12 and 34 wk gestation; de-
livery, 2 wk and 3 mo postpartum. Infant finger stick
blood will be collected at 2 wk and 3 mo.
For blood samples, 90 μL of venous blood will be
applied to each circle (× 4) of dried blood spot cards
(Whatman 903 Protein Saver). The card will be
protected in a clean environment out of direct
sunlight until dry. Ten cards will be sealed in a
multi-barrier pouch containing desiccant packs and
monitored for humidity on a weekly basis using
humidity indicator cards. The pouches will be stored
at room temperature until laboratory analyses.
Sections of amnion will be placed immediately in
cryovials and subsequently stored at−80C. Samples
will be shipped in part to UCD where procedures
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preparation and Illumina 450 k methylation analyses.
7) Deep phenotyping of metabolic and nutritional
status
Enhanced inflammation and oxidative stress
represent a “final common pathway” to intrauterine
growth retardation and are potentially mediated by a
number of different stimuli, including maternal diet
and nutritional status (e.g. energy inadequacy,
micronutrient deficiencies, fatty acid imbalance),
insulin resistance, poor water quality, recurrent
infectious stimuli, indoor air pollution, and maternal
stress (“allostatic load”). The effects of chronic
inflammation and oxidative stress have potential to
alter pregnancy outcomes, including the fetal and
postnatal growth potential, nutrient utilization and
nutritional status, and immunologic development
and function of mother and of the offspring. The
proposed LNS intervention, through anti-inflammatory
and antioxidant features, may beneficially alter the
maternal metabolic profile, especially for those who
initiate the LNS preconception.
The outcome represents deep phenotyping by
measuring in maternal tissues: hormones,
metabolites, measures of inflammation, oxidant
stress and immune function/status, and nutrient
biomarkers as possible indices of fundamental
metabolic alterations resulting from improved
long-term maternal nutrition in food insecure
populations. The potential contributions of these
assays include early prediction of impaired fetal
growth and possibly enhanced understanding of the
mechanisms responsible for growth improvements
in offspring of poor women provided with food
supplements.
Biological samples (blood, urine, fecal) will be collected
from all maternal participants who consent at delivery,
and at 14 d and 3 mo postpartum (Figure 2); additional
samples will be collected at 12 and 34-36 wk gestation in
Arms 1 and 2. The following assays will be performed:
 Maternal systemic and/or gastrointestinal
inflammatory markers: hsCRP, AGP, cytokines (IL-6,
IL-8, IL-10, TNF-α, IFN-γ); urine and fecal neopterin,
and fecal calprotectin, alpha-1-antitrypsin and
myeloperoxidase.
 Maternal oxidant status [33] will be assessed by mea-
suring oxidized-LDL and 4-HNE (4-hydroxynonenal,
produced during oxidative stress and subsequent
lipid peroxidation of polyunsaturated fatty acids).
 Maternal endocrinologic milieu will be assessed by
biomarkers of placental function: placental growth
hormone [34]; indices of iodine and energyutilization: thyroid hormone assays (TSH and
Reverse T3), serum glucose, insulin (and calculated
HOMA-IR: (fasting insulin [mLU/L]× fasting glu-
cose (mmol/l]/22/5)); leptin and adiponectin [35];
and maternal stress (“allostatic load”): serum cortico-
trophin releasing hormone (CRH).
 Maternal nutritional status will be assessed with the
following biomarkers: iron and zinc status (serum
ferritin, AGP, soluble transferrin receptor, zinc);
essential fatty acid profile; Vitamin B12 and
methylmalonic acid; 25-hydroxy Vitamin D; RBC
folate; retinol; pyridoxal phosphate, SAM/SAH,
homocysteine; alkaline phosphatase; albumin;
magnesium.
Infant finger stick samples will be utilized for epigen-
etic studies as first priority. Any residual blood will be
used for modified phenotyping. Infant stool samples will
also be analyzed for biomarkers of gut inflammation in-
cluding calprotectin, neopterin, alpha-1-antitrypsin and
myeloperoxidase.
8) Microbiome
The maternal intestinal microbiome will be
evaluated at 12 and 34-36 wk gestation and at delivery.
A partial stool sample will be collected at each time
point with the addition of a vaginal swab at delivery.
The contribution of this outcome is to provide insight
into the role of nutrition from conception on the
nature of the microbiome with all of the now
recognized implications of the latter for the
development of the host immune system and
nutritional status [36]. The microbiome will be
characterized by next-generation DNA sequencing
assays.
Partial fecal samples will be collected at 14 d and 3
mo to characterize the infant microbiome (as above).
As with other samples, the fecal samples for
microbiome will be used to compare with maternal
microbiome data.
9) Composition of breast milk
We hypothesize that improved maternal nutrition at
the time of greatest plasticity in early pregnancy will
favorably influence maternal metabolic and
nutritional status throughout pregnancy and thus
potentially the composition of breast milk in terms
of hormonal content, immune factors, cytokines,
and gut growth factors. Emerging data in the
literature support the impact of maternal metabolic
status on these bioactive factors [37]. The effects these
differences may have on early postnatal growth have
not been systematically examined.
This outcome will determine differences between
the three arms in composition of breast milk at 14 d
Figure 2 Blood collection and analyses for maternal longitudinal samples.
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growth factors, inflammatory mediators, hormones
and adipokines, markers of maternal oxidant stress
and antioxidant capacity of milk, all of which may
directly or indirectly influence infant growth and
development.Bioactive components of human milk for analyses:
 Nutrient composition: fatty acid profile;
macronutrients (lactose, protein, lipids, glucose);
selenium; iodine; Vitamin B12; folate; and Vitamin B6
 Growth factors (somatic and intestinal/mucosal
development and immunologic protection): IGF-1,
EGF (epidermal growth factor), TGF-α and TGF- β
 Cytokines: (IL-6, IL-8, IL-10, TNF-α, IFN-γ), and
hsCRP
 Hormones and adipokines: insulin, leptin, and
adiponectin
 Oxidative stress: F2-Isoprostanes, and 4-HNE
 Antioxidant capacity: total antioxidant capacity (TAC),
ferric reducing ability of plasma (or milk) (FRAP)Data management & statistics
Trial power and sample size
Sample size was determined to test the primary hypoth-
esis based on the primary outcome of LAZ at birth with
80% power at each individual site, while maintaining an
overall trial-wise Type I error rate of 0.05 across all
planned primary hypothesis tests (two tests comparing
Arm 1 vs Arm 2 and Arm 1 vs Arm 3 at each of four
sites). Thus an alpha level of 0.00625 was specified to ac-
count for the 8 planned primary comparisons. Assuming
an alpha level of 0.00625, a 2-sided test, and a standard
deviation of 1.0 for the primary outcome, LAZ, 192 eva-
luable women per arm at each site will allow detection
of an effect size of 0.37 with 80% power. Accounting for
20% attrition during pregnancy requires that 240 women
per arm enter Stage 2 at each site, and assuming that
50% of women randomized at Stage 1 will get pregnant
and move to Stage 2 requires 480 women per arm en-
rolled at each site. Keeping the number entering Stage 2
at 240 per arm, if attrition during pregnancy is 10% in-
stead of 20%, 216 evaluable women per arm will allow
detection of an effect size of 0.35.
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as primary, given 192 evaluable women per arm at each
site for a total of 768 women per arm over all four
sites, setting an alpha level of 0.025 for each primary
hypothesis test will allow detection of an effect size of
0.18 with 90% power or an effect size of 0.20 with 95%
power for each overall comparison. When data are
combined for identical trials undertaken in all four
participating countries, power will be sufficient to
demonstrate a significant reduction in incidence of
LBW between Arms 1 and 3 with a trend for decreas-
ing perinatal mortality.
Adverse events
Adverse events will be monitored continuously on an
ongoing basis by recording on a data form any of the
following situations:
 Any fatal or life threatening event occurs to the
participating woman, fetus or infant, or
 Any serious and unexpected adverse event occurs
The specific adverse events monitored in this trial in-
clude early termination of pregnancy, adverse pregnancy
outcome, adverse neonatal event, hospitalization (mother
or child) due to acute illness, allergic reactions, diarrhea,
and vomiting. All such events, including other unexpected
events will trigger completion of the adverse events form,
and will be reported to the site PI, the Data Coordinating
Center and the overall trial PI within 48 h for all deaths
and within 7 d for other adverse events.
Interim data monitoring and analyses
The Global Network Data Monitoring Committee (DMC),
designated by NICHD, will monitor the safety of the trial.
The DMC will monitor the trial for safety at approxi-
mately 6-m intervals, once all countries have commenced
recruitment. The adverse events enumerated above, as
well as other unexpected serious adverse events will be
tabulated by treatment group for the DMC to review.
While the DMC report will be masked to treatment group
(designated only as groups A, B and C) for routine moni-
toring, the DMC may be unmasked to comprehensively
review the safety profile for the trial participants.
The trial has no planned interim efficacy looks or rele-
vant stopping rules because the primary outcome is only
available at birth, with a large lag between recruitment/
randomization and availability of the primary outcome
(at least 12 mo), and a number of important secondary
outcomes are assessed at 6 mo of age.
Statistical analyses
This trial is designed to formally test mean differences
in the primary outcome of birth LAZ between womenrandomized to receive a daily nutrition supplement be-
ginning 3 or more months prior to conception (Arm 1)
and women randomized to receive the same daily nutri-
tion supplement beginning at 12 wk gestation (Arm 2), and
between Arm 1 and a control group of women (Arm 3)
who will not receive the nutrition supplement. Analyses
will be conducted separately by research site. In a sec-
ondary analysis outcomes will be compared across all
four sites using the combined data. Following an intent-
to-treat approach for all offspring who have a primary
outcome determined, individuals will be analyzed in the
intervention group to which they are assigned regard-
less of intervention received. The primary analysis will
compare mean LAZ between groups using a linear
model with LAZ as the outcome and intervention group
as the primary predictor to test the two primary hypoth-
eses, namely that: (1) mean LAZ at birth differs between
Arm 1 and Arm 2, and (2) mean LAZ at birth differs be-
tween Arm 1 and Arm 3. First, the two degree of free-
dom F-test will be used to test the hypothesis that the
mean LAZ in at least one arm differs from the other
two versus the null hypothesis that all three groups have
equal mean LAZ. If that test is significant at the 0.0125
level then the two primary hypotheses will be tested at the
0.00625 level. Secondary analyses using multivariable re-
gression models may adjust for the randomization cluster
and any other critical covariates or confounders that may
be imbalanced across the treatment groups (see below).
The same modeling approach will be used to evaluate the
trial hypotheses over all sites combined, while controlling
for research site.
Since the primary outcome of mean LAZ will only be
available on a subset of those randomized (women who
get pregnant and deliver a live birth, with LAZ evaluated),
we will ensure that we still have balance across the three
treatment groups for key covariates and confounders for
the group with the primary outcome available. These will
include factors such as maternal BMI, maternal age, parity,
and a summary measure for baseline socio economic sta-
tus. If there is any suggestion of imbalance on any of these
covariates across the three treatment groups (indicated by
p < 0.1), such covariate(s) will be adjusted for in the pri-
mary analysis for the primary and all secondary outcomes.
In addition, as a further check to ensure that evaluat-
ing only a subset of those randomized is not skewing the
results in any unexpected manner, we will construct a
composite binary secondary outcome that will be evalu-
ated alongside the primary outcome on all randomized
women who get pregnant. We provisionally define this
outcome as live birth free of growth failure, with the
latter defined as LAZ < −2 SD at or within 12 h of birth.
This and other binary outcomes (such as LBW and peri-
natal mortality) will be analyzed using chi-square tests
(unadjusted) or robust Poisson regression (adjusted for
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to produce estimates of relative risk [36].
Secondary outcomes evaluated will include infant growth
over the first 6 mo of life, prevalence of LBW, and preva-
lence of perinatal mortality (stillbirths and neonatal deaths
up to 1 mo of age). Infant growth will be examined based
on LAZ at birth, 0.5, 1, 3, and 6 mo with linear repeated
measures models using generalized estimating equation
methods with robust variance estimators to account for the
correlation of LAZ across time within individual infants.
Models will include terms for intervention group, time and
the group by time interaction to evaluate whether the three
groups differ in changes in mean LAZ across time. For the
longitudinal analyses, missing outcome measures will
be treated as missing at random. Other secondary out-
comes will be evaluated using model-based approaches
as applicable. The models will allow for inclusion of
covariates, such as socio-economic status, maternal age,
or maternal smoking, to account for potentially confound-
ing effects of baseline differences across groups. All
models using data combined over the four sites will con-
trol for research site.
Covariates that occur after randomization will not be
included in the primary models assessing intervention
group differences with respect to the primary outcome,
LAZ at birth, or secondary outcomes including infant
growth in the first 6 mo as these covariates may in the-
ory be affected by the intervention and lie in the causal
pathway between intervention and growth. However, in
subsequent analyses such as mediation analyses, factors
known to affect infant growth may be explored for direct
and indirect effects on outcomes.
Discussion
Innovation & significance
Key innovative features of this maternal nutrition inter-
vention project are [1] the longitudinal trial commen-
cing prior to conception, with, importantly, a range of
intervention intervals before conception (as birth size
is related to inter-pregnancy intervals [38]); [2] the pri-
mary focus on length, but with a wide range of public
health and laboratory outcomes; [3] the special em-
phasis on intervention-related changes in the epige-
nome of mother, fetus and infant; and [4] the relatively
large predicted effect size for the primary outcome of
newborn LAZ compared with that observed for maternal
nutrition interventions commencing when gestation is
well established.
Sustainability
Assuming that the primary hypothesis is correct, an im-
portant initial aspect of sustainability will be to ascertain
the longer term benefits of this trial. This project covers
the first half of the ‘First 1000 Days.’ Assuming thehypothesized benefits to fetal growth are confirmed, es-
pecially by enhanced early neonatal length, it will be of
outstanding importance to know the extent to which
beneficial outcomes of this preconception intervention
model are carried through to the second half of the ‘First
1000 Days’. Positive birth/early neonatal results will give
time to prepare economically and organizationally to
undertake anthropometry and tests of cognitive devel-
opment from 6 mo of age into early childhood.
Longer term, positive results of this project will make
a powerful case for shifting current paradigms on pre-
vention of retarded linear growth in the ‘First 1000 Days’
and its life-long adverse associations. The case will be
strengthened by the multi-country, multi-continent, multi-
cultural organization of this project which could, therefore,
without essential further confirmation, result in adjusted
strategies and recommendations. The promotion of optimal
preconception maternal diets by the world’s major health
organizations will be especially vital because of the implica-
tions for prioritizing promotion of optimal nutrition for all
women of child-bearing age (including adolescent girls),
which is a challenging task.
In addition to favorable anthropometric outcomes, en-
couragement to pursue measures for sustainability may
result from the outcomes of the associated laboratory re-
search, for example, evidence of reversing unfavorable epi-
genomic patterns by preconception nutrition intervention
with subsequent transmission of these favorable results to
the fetus.
Risks
This project is very low risk. The theoretical small risk
of increasing the frequency of cephalo-pelvic dispropor-
tion is being minimized by giving priority to inclusion of
participants who have had a previous uncomplicated vagi-
nal delivery and on deliveries in facilities that have caesar-
ian section capacity. Nulliparous women will not be
excluded provided delivery is in a facility equipped for
Caesarian sections. A second potential risk is increas-
ing prevalence of overweight/obesity in developing coun-
tries, including women of child-bearing age. These women
and their offspring may still benefit from micronutrient
supplements and, to minimize this risk, will not be candi-
dates for additional calorie-protein supplements.
Trial organization and management
Management plan for this project
Overall oversight of the project and leadership is pro-
vided by the Nutrition Program of the Bill & Melinda
Gates Foundation together with the International Scien-
tific Advisory Committee formed specifically for this pro-
ject and with the NICHD Global Network for Women’s
and Children’s Health Research (Steering Committee and
DMC) (Figure 3).
Trial Management Committee
University of Colorado PIs 
Overseas site PIs
Trial Coordinator
Data Coordinating Center
BMGF
& Scientific 
Advisory 
Committee
GN Steering Committee 
& DMC
Research Site Specific 
Ethics Review Boards
Figure 3 Organizational chart for month-to-month supervision of project.
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 University of Colorado Denver, Aurora, CO: Drs.
Hambidge and Krebs provide overall trial
management and oversight with support of J
Westcott, including fiscal management.
 Institute for Multidisciplinary Health (IMSALUD),
Guatemala City, Guatemala: Dr. Ana Garces provides
the in-country leadership for the Guatemala site.
 Aga Khan University (AKU), Karachi, Pakistan:
Dr. Omrana Pasha provides in-country leadership
for the Pakistan sites. AKU collaborates with
Dr. Robert Goldenberg, Columbia University, for the
Global Network, who will serve as an advisor and
interface with the Global Network.
 Jawaharlal Nehru Medical College (JNMC), Belgaum,
Karnataka, India: Drs. Bhala Kodkany and ShivaSITE DIR
PROJECT D
Research
Nutritionist
FIELD TEAM (c
DATA MANA
Network M
Data Entry 
Home Visitor Research 
Assistant (x15)
Field Coo
Field Supervisors (x2)
(Home)
Figure 4 Organization of individual research sites.Goudar provide in-country leadership of the trial. The
JNMC site collaborates with Dr. Richard Derman,
Christiana Health Care, for the Global Network.
 Kinshasa School of Public Health (KSPH), Kinshasa,
Democratic Republic of the Congo (DRC):
Dr. Antoinette Tshefu serves as the lead of the DRC
site. Dr. Carl Bose, University of North Carolina,
serves as the Global Network partner of the DRC site.
 RTI International, Durham, NC: Dr. Elizabeth
McClure serves as the director of the data center
activities at RTI for this project and the Global
Network, supported by Kristen Stolka and by
Dr. Abhik Das, the senior statistician of the
preconception trial.
Each research site has a cadre of trained research
personnel including physicians, nurses, research assistants,ECTOR
IRECTOR
luster level)
GEMENT
anager
Clerk (x3)
OPERATIONS
Administrator
Driver
Security
Housekeeping
Logistitian
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and laboratory technicians, who are trained in data and
sample collection, and data managers who oversee the
information technology, data entry and data edits.
Generally, the site organization is described in Figure 4.Additional file
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